KPV
Lysine-Proline-Valine
A three-amino-acid fragment of alpha-melanocyte-stimulating hormone with anti-inflammatory activity, most often used orally for gut-related inflammation and topically for skin.
- Category
- Immune & Gut
- Half-life
- Very short
- Cycle length
- 4–8 weeks typical
- Level
- beginner
Overview
KPV is the C-terminal tripeptide of alpha-MSH, the fragment responsible for much of that hormone's anti-inflammatory activity without its pigmentation effects. Its appeal is its size: small enough to be stable, cheap to produce, and usually taken orally or topically rather than injected — which makes it one of the more accessible entry points into the peptide world.
How it works
KPV is taken up into cells and acts to inhibit NF-κB signalling, a central pathway in inflammatory gene expression. By blocking that translocation, it reduces production of pro-inflammatory cytokines including TNF-α and IL-6. In the gut, this appears to reduce mucosal inflammation without the systemic effects of larger anti-inflammatory drugs.
Reported benefits
- Reduced intestinal inflammation in colitis models
- Anti-inflammatory effect via NF-κB inhibition
- Reported improvement in IBS-type symptoms
- Topical anti-inflammatory and antimicrobial activity
- Oral and topical routes available
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
Oral protocols are commonly described at 200–500 mcg per day, often in a single dose on an empty stomach. Topical formulations vary. Injectable protocols exist but are less common.
KPV is one of the few peptides where the oral route is genuinely plausible, because the tripeptide is small and reasonably stable. Most protocols run four to eight weeks.
Community-reported: 200–500 mcg orally or by injection once or twice daily, or a topical cream, in courses of one to four weeks.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
Preclinical work in colitis models is consistent and shows meaningful reductions in inflammatory markers and mucosal damage. Human data is very limited — mostly small studies and extensive anecdotal reporting around gut symptoms. The mechanism is well characterised even where the clinical evidence is not.
Preclinical & non-clinical data
A tripeptide fragment of alpha-MSH that retains anti-inflammatory signalling without the pigment effects. Its evidence is cell and animal work in colitis and skin inflammation models.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
Reported mainly for gut and skin inflammation. The gut accounts describe less bloating and discomfort within days, or no change at all. The skin accounts — a recurring theme for redness and rosacea-type flushing — report calmer skin over a few weeks with occasional stinging at first. Because people tend to try it alongside eliminating foods or changing a routine, the reports rarely isolate what did the work.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Generally reported as well tolerated
- Mild gastrointestinal discomfort
- Skin irritation with topical use
- Headache reported rarely
Safety notes
No human safety database of any size exists. Because it suppresses inflammatory signalling, anyone with an active infection should be cautious — inflammation is part of the immune response. Avoid in pregnancy.
Stacking
Frequently stacked with BPC-157 in gut-focused protocols, and with Thymosin Alpha-1 in broader immune stacks. Also combined with oral BPC-157 where the goal is mucosal repair.
Related compounds
Thymosin Alpha-1
Tα1, Zadaxin
Immune & Gut
An immune-modulating peptide with actual clinical approvals.
LL-37
Cathelicidin antimicrobial peptide — CAMP
Immune & Gut
A natural antimicrobial peptide with a two-sided immune reputation.
VIP
Vasoactive intestinal peptide — 28 amino acids
Immune & Gut
A signalling peptide central to immune tolerance and gut function.